[1]
|
Cai, Z. and Liu, Q. (2021) Understanding the Global Cancer Statistics 2018: Implications for Cancer Control. Science China Life Sciences, 64, 1017-1020. https://doi.org/10.1007/s11427-019-9816-1
|
[2]
|
Hoefnagel, S., Boonstra, J.J., Russchen, M., et al. (2021) Towards Personalized Treatment Strategies for Esophageal Adenocarcinoma; A Review on the Molecular Characterization of Esophageal Adenocarcinoma and Current Research Efforts on Individualized Curative Treatment Regimens. Cancers, 13, Article 4881.
https://doi.org/10.3390/cancers13194881
|
[3]
|
Li, Q., Liu, T. and Ding, Z. (2022) Neoadjuvant Immunotherapy for Resectable Esophageal Cancer: A Review. Frontiers in Immunology, 13, Article 1051841. https://doi.org/10.3389/fimmu.2022.1051841
|
[4]
|
Han, D., Li, B., Zhao, Q., et al. (2022) The Key Clinical Ques-tions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancer-A Review. Frontiers in Oncology, 12, Arti-cle ID: 890688.
https://doi.org/10.3389/fonc.2022.890688
|
[5]
|
Yan, Y., Feng, X., Li, C., et al. (2022) Treatments for Resectable Esophageal Cancer: From Traditional Systemic Therapy to Immunotherapy. Chinese Medical Journal, 135, 2143-2156.
https://doi.org/10.1097/CM9.0000000000002371
|
[6]
|
Wang, Z., Shao, C., Wang, Y., et al. (2022) Efficacy and Safety of Neoadjuvant Immunotherapy in Surgically Resectable Esophageal Cancer: A Systematic Review and Me-ta-Analysis. International Journal of Surgery, 104, Article ID: 106767. https://doi.org/10.1016/j.ijsu.2022.106767
|
[7]
|
Fang, P., Zhou, J., Liang, Z., et al. (2022) Immunotherapy Re-sistance in Esophageal Cancer: Possible Mechanisms and Clinical Implications. Frontiers in Immunology, 13, Article 975986. https://doi.org/10.3389/fimmu.2022.975986
|
[8]
|
Waters, J.K. and Reznik, S.I. (2022) Update on Man-agement of Squamous Cell Esophageal Cancer. Current Oncology Reports, 24, 375-385. https://doi.org/10.1007/s11912-021-01153-4
|
[9]
|
Olivo, S.A., Macedo, L.G., Gadotti, I.C., et al. (2008) Scales to Assess the Quality of Randomized Controlled Trials: A Systematic Review. Physical Therapy, 88, 156-175. https://doi.org/10.2522/ptj.20070147
|
[10]
|
Sun, J.M., Shen, L., Shah, M.A., et al. (2021) Pembrolizumab plus Chemotherapy versus Chemotherapy Alone for First-Line Treatment of Advanced Oesophageal Cancer (KEYNOTE-590): A Randomised, Placebo-Controlled, Phase 3 Study. Lancet, 398, 759-771. https://doi.org/10.1016/S0140-6736(21)01234-4
|
[11]
|
Kato, K., Cho, B.C., Takahashi, M., et al. (2019) Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant to Pre-vious Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 20, 1506-1517.
https://doi.org/10.1016/S1470-2045(19)30626-6
|
[12]
|
Kojima, T., Shah, M.A., Muro, K., et al. (2020) Randomized Phase III KEYNOTE-181 Study of Pembrolizumab versus Chemotherapy in Advanced Esophageal Cancer. Journal of Clinical Oncology, 38, 4138-4148.
https://doi.org/10.1200/JCO.20.01888
|
[13]
|
Wang, Z.X., Cui, C., Yao, J., et al. (2022) Toripalimab plus Chemo-therapy in Treatment-Naive, Advanced Esophageal Squamous Cell Carcinoma (JUPITER-06): A Multi-Center Phase 3 Trial. Cancer Cell, 40, 277-288.
https://doi.org/10.1016/j.ccell.2022.02.007
|
[14]
|
Huang, J., Xu, J., Chen, Y., et al. (2020) Camrelizumab versus In-vestigator’s Choice of Chemotherapy as Second-Line Therapy for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma (ESCORT): A Multicentre, Randomised, Open-Label, Phase 3 Study. The Lancet Oncology, 21, 832-842. https://doi.org/10.1016/S1470-2045(20)30110-8
|
[15]
|
Luo, H., Lu, J., Bai, Y., et al. (2021) Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. JAMA, 326, 916-925. https://doi.org/10.1001/jama.2021.12836
|
[16]
|
Xu, J., Li, Y., Fan, Q., et al. (2022) Clinical and Biomarker Analyses of Sintilimab versus Chemotherapy as Second-Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Car-cinoma: A Randomized, Open-Label Phase 2 Study (ORIENT-2). Nature Communications, 13, Article No. 857.
https://doi.org/10.1038/s41467-022-28408-3
|
[17]
|
Janjigian, Y.Y., Shitara, K., Moehler, M., et al. (2021) First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, Gastro-Oesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet, 398, 27-40. https://doi.org/10.1016/S0140-6736(21)00797-2
|
[18]
|
Doki, Y., Ajani, J.A., Kato, K., et al. (2022) Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma. The New England Journal of Medicine, 386, 449-462. https://doi.org/10.1056/NEJMoa2111380
|
[19]
|
Cao, W., Chen, H.D., Yu, Y.W., et al. (2020) Changing Profiles of Cancer Burden Worldwide and in China: A Secondary Analysis of the Global Cancer Statistics. Chinese Medical Journal, 134, 783-791.
https://doi.org/10.1097/CM9.0000000000001474
|
[20]
|
Attia, H. and Smyth, E. (2021) Evolving Therapies in Ad-vanced Oesophago-Gastric Cancers and the Increasing Role of Immunotherapy. Expert Review of Anticancer Therapy, 21, 535-546.
https://doi.org/10.1080/14737140.2021.1866548
|
[21]
|
Freeman, G.J., Long, A.J., Iwai, Y., et al. (2000) Engage-ment of the PD-1 Immunoinhibitory Receptor by A Novel B7 Family Member Leads to Negative Regulation of Lym-phocyte Activation. Journal of Experimental Medicine, 192, 1027-1034. https://doi.org/10.1084/jem.192.7.1027
|
[22]
|
Cao, S., Li, J., Lu, J., et al. (2019) Mycobacterium Tuberculosis Anti-gens Repress Th1 Immune Response Suppression and Promotes Lung Cancer Metastasis through PD-1/PDl-1 Signaling Pathway. Cell Death & Disease, 10, Article No. 44. https://doi.org/10.1038/s41419-018-1237-y
|
[23]
|
Suzuki, K., Tajima, M., Tokumaru, Y., et al. (2023) Anti-PD-1 Antibodies Recognizing the Membrane-Proximal Region Are PD-1 Agonists That Can Down-Regulate Inflammatory Diseases. Science Immunology, 8, eadd4947.
https://doi.org/10.1126/sciimmunol.add4947
|
[24]
|
Tan, Z., Chiu, M.S., Yang, X., et al. (2023) Isoformic PD-1-Mediated Immunosuppression Underlies Resistance to PD-1 Blockade in Hepatocellular Carcinoma Patients. Gut, 72, 1568-1580. https://doi.org/10.1136/gutjnl-2022-327133
|
[25]
|
Rousseau, B., Bieche, I., Pasmant, E., et al. (2022) PD-1 Blockade in Solid Tumors with Defects in Polymerase Epsilon. Cancer Discovery, 12, 1435-1448. https://doi.org/10.1158/2159-8290.CD-21-0521
|
[26]
|
Kanie, K., Iguchi, G., Bando, H., et al. (2021) Mechanistic Insights into Immune Checkpoint Inhibitor-Related Hypophysitis: A Form of Paraneoplastic Syndrome. Cancer Immu-nology, Immunotherapy, 70, 3669-3677.
https://doi.org/10.1007/s00262-021-02955-y
|
[27]
|
Makker, V., Colombo, N., Casado, H.A., et al. (2023) Len-vatinib plus Pembrolizumab in Previously Treated Advanced Endometrial Cancer: Updated Efficacy and Safety from the Randomized Phase III Study 309/KEYNOTE-775. Journal of Clinical Oncology, 41, 2904-2910. https://doi.org/10.1200/JCO.22.02152
|
[28]
|
Wang, B.C., Zhang, Z.J., Fu, C., et al. (2019) Efficacy and Safety of Anti-PD-1/PD-L1 Agents vs Chemotherapy in Patients with Gastric or Gastroesophageal Junction Cancer: A Systematic Review and Meta-Analysis. Medicine, 98, e18054. https://doi.org/10.1097/MD.0000000000018054
|
[29]
|
Yang, L., Dong, X.Z., Xing, X.X., et al. (2020) Efficacy and Safety of Anti-PD-1/Anti-PD-L1 Antibody Therapy in Treatment of Advanced Gastric Cancer or Gastroesophageal Junction Cancer: A Meta-Analysis. World Journal of Gastrointestinal Oncology, 12, 1346-1363. https://doi.org/10.4251/wjgo.v12.i11.1346
|